Bobak R. Azamian - 24 Dec 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
President/CEO and Board Chair, Director
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
24 Dec 2025
Net transactions value
-$495,089
Form type
4
Filing time
30 Dec 2025, 16:26:13 UTC
Previous filing
08 Dec 2025
Next filing
09 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Azamian Bobak R. President/CEO and Board Chair, Director C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE /s/ Jeffrey Farrow, Attorney-in-Fact 30 Dec 2025 0001827672

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Sale $448,558 -5,443 -0.63% $82.41 858,548 24 Dec 2025 By the Bobak Azamian Living Trust established April 16, 2018 F1, F2, F3
transaction TARS Common Stock Sale $46,532 -557 -0.06% $83.54 857,991 24 Dec 2025 By the Bobak Azamian Living Trust established April 16, 2018 F1, F3, F4
holding TARS Common Stock 1,750 24 Dec 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2024.
F2 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $81.89 to $82.88. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.
F4 The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $83.14 to $84.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.